EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Eikon Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.70+0.28 (+3.77%)
Close on Oct 19, 2026
- Market cap
- $416.90M
- P/E (TTM)
- –
- Dividend yield
- –
Eikon Therapeutics, Inc. cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 9.89
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 257.9%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.89
- Dividend yield
- –